|
1
|
Bedke J, Gauler T, Grünwald V, Hegele A,
Herrmann E, Hinz S, Janssen J, Schmitz S, Schostak M, Tesch H, et
al: Systemic therapy in metastatic renal cell carcinoma. World J
Urol. 35:179–188. 2017.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Flippot R, Escudier B and Albiges L:
Immune checkpoint inhibitors: Toward new paradigms in renal cell
carcinoma. Drugs. 78:1443–1457. 2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Motzer RJ, Escudier B, McDermott DF,
George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G,
Plimack ER, et al: Nivolumab versus everolimus in advanced
renal-cell carcinoma. N Engl J Med. 373:1803–1813. 2015.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Motzer RJ, Tannir NM, McDermott DF,
Frontera OA, Melichar B, Choueiri TK, Plimack ER, Barthélémy P,
Porta C, George S, et al: Nivolumab plus ipilimumab versus
sunitinib in advanced renal-cell carcinoma. N Engl J Med.
378:1277–1290. 2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Rini BI, Plimack ER, Stus V, Gafanov R,
Hawkins R, Nosov D, Pouliot F, Alekseev B, Soulières D, Melichar B,
et al: Pembrolizumab plus axitinib versus sunitinib for advanced
renal-cell carcinoma. N Engl J Med. 380:1116–1127. 2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Motzer RJ, Penkov K, Haanen J, Rini B,
Albiges L, Campbell MT, Venugopal B, Kollmannsberger C, Negrier S,
Uemura M, et al: Avelumab plus axitinib versus sunitinib for
advanced renal-cell carcinoma. N Engl J Med. 380:1103–1115.
2019.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Motzer RJ, Bacik J, Murphy BA, Russo P and
Mazumdar M: Interferon-alfa as a comparative treatment for clinical
trials of new therapies against advanced renal cell carcinoma. J
Clin Oncol. 20:289–296. 2002.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Heng DY, Xie W, Regan MM, Warren MA,
Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, et al:
Prognostic factors for overall survival in patients with metastatic
renal cell carcinoma treated with vascular endothelial growth
factor-targeted agents: Results from a large, multicenter study. J
Clin Oncol. 27:5794–5799. 2009.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Motzer RJ, Bacik J, Schwartz LH, Reuter V,
Russo P, Marion S and Mazumdar M: Prognostic factors for survival
in previously treated patients with metastatic renal cell
carcinoma. J Clin Oncol. 22:454–463. 2004.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Ko JJ, Xie W, Kroeger N, Lee JL, Rini BI,
Knox JJ, Bjarnason GA, Srinivas S, Pal SK, Yuasa T, et al: The
international metastatic renal cell carcinoma database consortium
model as a prognostic tool in patients with metastatic renal cell
carcinoma previously treated with first-line targeted therapy: A
population-based study. Lancet Oncol. 16:293–300. 2015.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Suzuki K, Terakawa T, Furukawa J, Harada
K, Hinata N, Nakano Y and Fujisawa M: C-reactive protein and the
neutrophil-to-lymphocyte ratio are prognostic biomarkers in
metastatic renal cell carcinoma patients treated with nivolumab.
Int J Clin Oncol. 25:135–144. 2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Martini DJ, Liu Y, Shabto JM, Carthon BC,
Hitron EE, Russler GA, Caulfield S, Kissick HT, Harris WB, Kucuk O,
et al: Novel risk scoring system for patients with metastatic renal
cell carcinoma treated with immune checkpoint inhibitors.
Oncologist. 25:e484–e491. 2020.PubMed/NCBI View Article : Google Scholar
|
|
13
|
De Giorgi U, Procopio G, Giannarelli D,
Sabbatini R, Bearz A, Buti S, Basso U, Mitterer M, Ortega C, Bidoli
P, et al: Association of systemic inflammation index and body mass
index with survival in patients with renal cell cancer treated with
nivolumab. Clin Cancer Res. 25:3839–3846. 2019.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Raimondi A, Sepe P, Zattarin E, Mennitto
A, Stellato M, Claps M, Guadalupi V, Verzoni E, de Braud F and
Procopio G: Predictive biomarkers of response to immunotherapy in
metastatic renal cell cancer. Front Oncol. 10(1644)2020.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Ishihara H, Tachibana H, Takagi T, Kondo
T, Fukuda H, Yoshida K, Iizuka J, Kobayashi H, Okumi M, Ishida H
and Tanabe K: Predictive impact of peripheral blood markers and
C-reactive protein in nivolumab therapy for metastatic renal cell
carcinoma. Target Oncol. 14:453–463. 2019.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Perrone F, Minari R, Bersanelli M, Bordi
P, Tiseo M, Favari E, Sabato R and Buti S: The prognostic role of
high blood cholesterol in advanced cancer patients treated with
immune checkpoint inhibitors. J Immunother. 43:196–203.
2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Bruce-Chwatt LJ: Declaration of Helsinki.
Recommendations guiding doctors in clinical research. WHO Chron.
19:31–32. 1965.PubMed/NCBI
|
|
18
|
Hu B, Yang XR, Xu Y, Sun YF, Sun C, Guo W,
Zhang X, Wang WM, Qiu SJ, Zhou J and Fan J: Systemic
immune-inflammation index predicts prognosis of patients after
curative resection for hepatocellular carcinoma. Clin Cancer Res.
20:6212–6222. 2014.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009.PubMed/NCBI View Article : Google Scholar
|
|
20
|
R Core Team (2020). R: A language and
environment for statistical computing. R Foundation for Statistical
Computing, Vienna, Austria. URL http://www.R-project.org/. Accessed June 14, 2020.
|
|
21
|
Hinata N, Yonese J, Masui S, Nakai Y,
Shirotake S, Tatsugami K, Inamoto T, Nozawa M, Ueda K, Etsunaga T,
et al: A multicenter retrospective study of nivolumab monotherapy
in previously treated metastatic renal cell carcinoma patients:
Interim analysis of Japanese real-world data. Int J Clin Oncol.
25:1533–1542. 2020.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Tomita Y, Fukasawa S, Shinohara N,
Kitamura H, Oya M, Eto M, Tanabe K, Kimura G, Yonese J, Yao M, et
al: Nivolumab versus everolimus in advanced renal cell carcinoma:
Japanese subgroup analysis from the CheckMate 025 study. Jpn J Clin
Oncol. 47:639–646. 2017.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Yip SM, Wells C, Moreira R, Wong A,
Srinivas S, Beuselinck B, Porta C, Sim HW, Ernst DS, Rini BI, et
al: Checkpoint inhibitors in patients with metastatic renal cell
carcinoma: Results from the international metastatic renal cell
carcinoma database consortium. Cancer. 124:3677–3683.
2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Tamura K, Matsushita Y, Watanabe H,
Motoyama D, Ito T, Sugiyama T, Otsuka A and Miyake H: Feasibility
of the ACL (albumin, C-reactive protein and lactate dehydrogenase)
model as a novel prognostic tool in patients with metastatic renal
cell carcinoma previously receiving first-line targeted therapy.
Urol Oncol. 38:6.e9–6.e16. 2020.PubMed/NCBI View Article : Google Scholar
|
